Diseases (25)
Screening/Initial Testing (1)

Note:

May be considered in patients with suspected or known familial cancer syndrome(s). Typically testing is every 6 months beginning at age 30.

Other Supportive/Alternative Tests (10)

Note:

Elevated CA-125 is seen in patients with pelvic actinomycosis.


Note:

Aid in diagnosis and management of ovarian cancer.


Note:

Not specific, but supportive of diagnosis and treatment.


Note:

Not specific, but might be supportive for diagnosis and treatment.


Note:

Not specific for testicular cancer, but might be supportive for diagnosis and treatment.


Note:

Not specific for breast cancer, but might be supportive for diagnosis and treatment.


Note:

Not specific for kidney cancer, but might be supportive for diagnosis and treatment.


Note:

Not specific, but supportive for diagnosis and treatment.


Note:

Not specific for mesothelioma, but can be supportive.


Note:

Not specific, but supportive.

Overview

CA 125 is a cell surface protein often found on ovarian cancer cells and in some normal tissues. It is one of the protein antigens that has been associated with the presence of various cancers, but is most often positive in ovarian cancer. CA 125 concentrations may also be elevated in other types of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease. CA 125 is a useful tumor marker for evaluating therapy and monitoring disease status in ovarian cancer patients. As the levels decrease it is an indication that the therapy or treatment is working. Post-operatively, the CA 125 concentration correlates with tumor bulk and is a prognostic indicator of clinical outcome. It has been reported that patients with levels exceeding 35 U/mL have the highest risk for clinical recurrence. CA 125 is not useful as a screening mechanism because it is elevated in many non-cancerous conditions, although women that are at higher risk due to family history or other reasons are usually tested regularly as a precautionary method.

Measured serially, serum CA 125 concentration typically corresponds with disease progression or regression. The rate of change in CA 125 is also highly prognostic. A rapid decrease in the level of CA 125 indicates a positive response to treatment. Elevated levels of CA 125 after the third course of primary chemotherapy are typically predictive of poor outcomes.

Clinical Utility

  • Monitoring and management of ovarian cancer of epithelial type, including monitoring for disease after initial treatment.
  • Management of ovarian epithelial cancer patients with metastatic disease by monitoring the progression or regression of disease response to treatment

Interpretation

Increased in:

  • Ovarian cancer of epithelial types
  • Pelvic inflammatory disease
  • Some other cancers
  • Cancer of endometrium
  • Cancer of fallopian tube
  • Some physiological conditions such as pregnancy, menstruation
  • Endometriosis
  • Ovarian cysts

Note: Normal levels do not exclude recurrent malignancy.

Reference Ranges

 <30 U/mL

 

 

Methodology

Enzyme Immunoassay, ELISA

Specimen Collection

Serum (SST)

Stability:

  • Ambient: 24 hours
  • Refrigerated: 7 days
  • Frozen: 60 days
  • Separate sample within 1 hour of collection and keep refrigerated or frozen.

Additional Testing

Carcinoembryonic antigen (CEA), CA 15-3, CA 19-9, Follicle Stimulating Hormone, Luteinizing Hormone, HCG, Progesterone, HE4.

CPT
86304$20.81

ICD10
  • AK - Alaska
  • AL - Alabama
  • AR - Arkansas
  • AS - American Samoa
  • AZ - Arizona
  • CA - California - Entire State
  • CO - Colorado
  • CT - Connecticut
  • DC - District of Columbia
  • DE - Delaware
  • FL - Florida
  • GA - Georgia
  • GU - Guam
  • HI - Hawaii
  • IA - Iowa
  • ID - Idaho
  • IL - Illinois
  • IN - Indiana
  • KS - Kansas
  • KY - Kentucky
  • LA - Louisiana
  • MA - Massachusetts
  • MD - Maryland
  • ME - Maine
  • MI - Michigan
  • MN - Minnesota
  • MO - Missouri - Entire State
  • MS - Mississippi
  • MT - Montana
  • NC - North Carolina
  • ND - North Dakota
  • NE - Nebraska
  • NH - New Hampshire
  • NJ - New Jersey
  • NM - New Mexico
  • NV - Nevada
  • NY - New York - Entire State
  • OH - Ohio
  • OK - Oklahoma
  • OR - Oregon
  • PA - Pennsylvania
  • PR - Puerto Rico
  • RI - Rhode Island
  • SC - South Carolina
  • SD - South Dakota
  • TN - Tennessee
  • TX - Texas
  • UT - Utah
  • VA - Virginia
  • VI - Virgin Islands
  • VT - Vermont
  • WA - Washington
  • WI - Wisconsin
  • WV - West Virginia
  • WY - Wyoming
  • CNMI - Northern Mariana Islands
  • EM - Missouri - Northeastern & Southern
  • WM - Missouri - Northwestern
  • DN - New York - Downstate
  • QN - New York - Queens
  • UN - New York - Upstate
  • NF - California - Northern
  • SF - California - Southern
Showing results for all states.
Filter:
ICD10 CODE AND DESCRIPTIONLCD CODENCD CODE
A42 - Actinomycosis
A42.0 - Pulmonary actinomycosis
A42.1 - Abdominal actinomycosis
A42.2 - Cervicofacial actinomycosis
A42.7 - Actinomycotic sepsis
A42.8 - Other forms of actinomycosis
A42.81 - Actinomycotic meningitis
A42.82 - Actinomycotic encephalitis
A42.89 - Other forms of actinomycosis
A42.9 - Actinomycosis, unspecified
B44 - Aspergillosis
B44.9 - Aspergillosis, unspecified
C22 - Malignant neoplasm of liver and intrahepatic bile ducts
C22.0 - Liver cell carcinoma
C22.8 - Malignant neoplasm of liver, primary, unspecified as to type
C25 - Malignant neoplasm of pancreas
C25.0 - Malignant neoplasm of head of pancreas
C25.1 - Malignant neoplasm of body of pancreas
C25.2 - Malignant neoplasm of tail of pancreas
C25.4 - Malignant neoplasm of endocrine pancreas
C25.7 - Malignant neoplasm of other parts of pancreas
C25.8 - Malignant neoplasm of overlapping sites of pancreas
C25.9 - Malignant neoplasm of pancreas, unspecified
C38 - Malignant neoplasm of heart, mediastinum and pleura
C38.0 - Malignant neoplasm of heart
C38.1 - Malignant neoplasm of anterior mediastinum
C38.2 - Malignant neoplasm of posterior mediastinum
C38.3 - Malignant neoplasm of mediastinum, part unspecified
C38.4 - Malignant neoplasm of pleura
C38.8 - Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
C39 - Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs
C39.0 - Malignant neoplasm of upper respiratory tract, part unspecified
C43.52 - Malignant melanoma of skin of breast
C44 - Other and unspecified malignant neoplasm of skin
C45 - Mesothelioma
C45.0 - Mesothelioma of pleura
C45.1 - Mesothelioma of peritoneum
C45.2 - Mesothelioma of pericardium
C45.7 - Mesothelioma of other sites
C45.9 - Mesothelioma, unspecified
C48 - Malignant neoplasm of retroperitoneum and peritoneum
C48.0 - Malignant neoplasm of retroperitoneum
C48.1 - Malignant neoplasm of specified parts of peritoneum
C48.2 - Malignant neoplasm of peritoneum, unspecified
C48.8 - Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49 - Malignant neoplasm of other connective and soft tissue
C49.8 - Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9 - Malignant neoplasm of connective and soft tissue, unspecified
C50 - Malignant neoplasm of breast
C50.01 - Malignant neoplasm of nipple and areola, female

Additional ICD10
  • AK - Alaska
  • AL - Alabama
  • AR - Arkansas
  • AS - American Samoa
  • AZ - Arizona
  • CA - California - Entire State
  • CO - Colorado
  • CT - Connecticut
  • DC - District of Columbia
  • DE - Delaware
  • FL - Florida
  • GA - Georgia
  • GU - Guam
  • HI - Hawaii
  • IA - Iowa
  • ID - Idaho
  • IL - Illinois
  • IN - Indiana
  • KS - Kansas
  • KY - Kentucky
  • LA - Louisiana
  • MA - Massachusetts
  • MD - Maryland
  • ME - Maine
  • MI - Michigan
  • MN - Minnesota
  • MO - Missouri - Entire State
  • MS - Mississippi
  • MT - Montana
  • NC - North Carolina
  • ND - North Dakota
  • NE - Nebraska
  • NH - New Hampshire
  • NJ - New Jersey
  • NM - New Mexico
  • NV - Nevada
  • NY - New York - Entire State
  • OH - Ohio
  • OK - Oklahoma
  • OR - Oregon
  • PA - Pennsylvania
  • PR - Puerto Rico
  • RI - Rhode Island
  • SC - South Carolina
  • SD - South Dakota
  • TN - Tennessee
  • TX - Texas
  • UT - Utah
  • VA - Virginia
  • VI - Virgin Islands
  • VT - Vermont
  • WA - Washington
  • WI - Wisconsin
  • WV - West Virginia
  • WY - Wyoming
  • CNMI - Northern Mariana Islands
  • EM - Missouri - Northeastern & Southern
  • WM - Missouri - Northwestern
  • DN - New York - Downstate
  • QN - New York - Queens
  • UN - New York - Upstate
  • NF - California - Northern
  • SF - California - Southern
Showing results for all states.
Filter:
ICD10 CODE AND DESCRIPTIONLCD CODENCD CODE
A42.0 - Pulmonary actinomycosis
A42.1 - Abdominal actinomycosis
A42.2 - Cervicofacial actinomycosis
A42.7 - Actinomycotic sepsis
A42.8 - Other forms of actinomycosis
A42.81 - Actinomycotic meningitis
A42.82 - Actinomycotic encephalitis
A42.89 - Other forms of actinomycosis
A42.9 - Actinomycosis, unspecified
B44.0 - Invasive pulmonary aspergillosis
B44.1 - Other pulmonary aspergillosis
B44.2 - Tonsillar aspergillosis
B44.7 - Disseminated aspergillosis
B44.8 - Other forms of aspergillosis
B44.81 - Allergic bronchopulmonary aspergillosis
B44.89 - Other forms of aspergillosis
B44.9 - Aspergillosis, unspecified
C22.0 - Liver cell carcinoma
C22.1 - Intrahepatic bile duct carcinoma
C22.2 - Hepatoblastoma
C22.3 - Angiosarcoma of liver
C22.4 - Other sarcomas of liver
C22.7 - Other specified carcinomas of liver
C22.8 - Malignant neoplasm of liver, primary, unspecified as to type
C22.9 - Malignant neoplasm of liver, not specified as primary or secondary
C25.0 - Malignant neoplasm of head of pancreas
C25.1 - Malignant neoplasm of body of pancreas
C25.2 - Malignant neoplasm of tail of pancreas
C25.3 - Malignant neoplasm of pancreatic duct
C25.4 - Malignant neoplasm of endocrine pancreas
C25.7 - Malignant neoplasm of other parts of pancreas
C25.8 - Malignant neoplasm of overlapping sites of pancreas
C25.9 - Malignant neoplasm of pancreas, unspecified
C38.0 - Malignant neoplasm of heart
C38.1 - Malignant neoplasm of anterior mediastinum
C38.2 - Malignant neoplasm of posterior mediastinum
C38.3 - Malignant neoplasm of mediastinum, part unspecified
C38.4 - Malignant neoplasm of pleura
C38.8 - Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
C39.0 - Malignant neoplasm of upper respiratory tract, part unspecified
C39.9 - Malignant neoplasm of lower respiratory tract, part unspecified
C44.0 - Other and unspecified malignant neoplasm of skin of lip
C44.00 - Unspecified malignant neoplasm of skin of lip
C44.01 - Basal cell carcinoma of skin of lip
C44.02 - Squamous cell carcinoma of skin of lip
C44.09 - Other specified malignant neoplasm of skin of lip
C44.1 - Other and unspecified malignant neoplasm of skin of eyelid, including canthus
C44.10 - Unspecified malignant neoplasm of skin of eyelid, including canthus
C44.101 - Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus
C44.102 - Unspecified malignant neoplasm of skin of right eyelid, including canthus

References